Peptide Friend answers peptide research questions
A few loose ends from the longer conversations.
What is Semax peptide used for?
Its prescription registrations in Russia and Ukraine concern ischemic stroke, transient ischemic attack, cognitive impairment and optic-nerve disease. Experimental work includes rat cortical ischemia and spinal-cord injury in female mice. Community claims about ordinary concentration extend beyond those injury experiments. I revisit the regional rat-brain findings when a claim grows larger than its experiment.
How does Selank work?
The molecular review describes modulation of GABA-receptor binding in rat-brain membranes. Selank also inhibited enkephalin-degrading enzymes in human plasma in vitro, changed GABA-related gene expression in rat frontal cortex, and altered immune signals in patients with anxiety-asthenic disorders. Those experiments concern several systems and several kinds of measurement. They leave substantial human interaction questions.
What does Selank do in people?
A small Russian anxiety study reported anxiety relief and mild activation, with no sedation, cognitive impairment or withdrawal in that study. The limited population and lack of independent Western replication constrain that result. Community descriptions of calm focus are anecdotal accounts, not clinical evidence. The Selank page discusses both the clinical finding and the safety gaps.
Does DSIP really work for sleep?
The 1981 study in six chronic insomniacs reported longer, less interrupted sleep, with improvement in the second hour and slight arousal in the first. A 2006 review remained unconvinced by the sleep literature overall. The pilot earns my interest; the general sleep claim remains unresolved. The DSIP research study overview also separates the later mouse fusion-peptide work from native DSIP.
Are these peptides safe?
Long-term safety in large, rigorous human trials remains unestablished for all three. Research-labelled material adds uncertainties about identity, purity and sterility, while the molecules bring their own unresolved interaction questions. The small studies cannot characterize pregnancy, breastfeeding or repeated exposure in people with significant medical conditions. The DSIP safety data make the size of those gaps particularly apparent.
Can Semax and Selank be combined?
A controlled human study establishing the benefit and safety of that combination is absent from the record here. Their overlapping biological activities leave plausible interaction questions. I’d leave the combination claim open until someone tests the combination itself. The comparison explains why the separate studies cannot settle it.